Please login to the form below

aclidinium

This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017. ... Duaklir (aclidinium/formoterol)

Latest news

Circassia exits allergy R&D after placebo effect strikes again

Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
GSK's triple COPD therapy tops Symbicort in phase III trial

These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
GSK brings forward triple COPD therapy filing in US

GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
Boehringer bags FDA approval for Spiriva-based combo

AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
GSK sees COPD future in triple therapy

Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Interview: Jorge Gallardo, Almirall

We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Editor – Medical Education Agency – Bucks: Salary TBC

Director – Healthcare PR: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director, Medical Education: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...